Related Experiment Video
Updated: Mar 9, 2026
Author Spotlight: Unveiling Transmembrane Protein Family-Related Markers in Gastric Cancer and Implications for Targeted Therapies
Published on: September 15, 2023
Tat-Interacting Protein 30 (TIP30) Expression Serves as a New Biomarker for Tumor Prognosis: A Systematic Review and
Tao Xu1,2, Zhichao Jin1, Yuan Yuan1,3
1Department of Oncology, Guang'anmen Hospital, China Academy of Chinese Medicine Sciences, Xicheng District, Beijing, China.
Background:
Tat-interacting protein 30 (TIP30) is a tumor suppressor protein that has been found to be expressed in a wide variety of tumor tissues. TIP30 is involved in the control of cell apoptosis, growth, metastasis, angiogenesis, DNA repair, and tumor cell metabolism. The methylation of the TIP30 promoter is also associated with tumor prognosis. To evaluate this topic further, we conducted a systematic meta-analysis to explore the clinicopathological and prognostic significance of TIP30 for tumor patients.
Methods:
We searched PubMed and EMBASE for eligible studies. We manually searched for printed journals and relevant textbooks. Subgroup analyses were performed based on the region, manuscript quality, methods of vasculogenic mimicry identification, pathology, and number of patients.
Results:
Fourteen studies with 1705 patients were included in this meta-analysis. A significant association was observed between high expression of TIP30 in patients with cancer with a good overall survival (hazard ratio = 0.53, 95% confidence interval: 0.41-0.69), and good recurrence-free survival or disease free survival (hazard ratio = 0.49, 95% confidence interval: 0.37-0.66). Lack of expression of TIP30 had an association with lymph node metastasis (odds ratio = 3.90, 95% confidence interval: 2.21-6.89) and high tumor node metastasis clinical stage (odds ratio = 2.10, 95% confidence interval: 1.68-2.62). The methylation of the TIP30 promoter did not significantly influence the overall survival (hazard ratio = 0.99, 95% confidence interval: 0.88-1.13) or disease free survival (hazard ratio = 0.62, 95% confidence interval: 0.19-2.02).
Conclusions:
TIP30 expression is associated with a good prognosis in patients with tumors. Clinical studies with large samples are needed worldwide and standardized protocols should be adopted in the future to achieve a better understanding of the relationship between tumor prognosis and TIP30.
Insights
High expression of Tat-interacting protein 30 (TIP30) is linked to better survival in cancer patients. TIP30 expression also correlates with less lymph node metastasis and lower clinical stage, indicating a good prognosis.
Area of Science:
- Oncology
- Molecular Biology
- Genetics
Background:
- Tat-interacting protein 30 (TIP30) is a known tumor suppressor.
- TIP30 plays a role in apoptosis, cell growth, metastasis, angiogenesis, DNA repair, and tumor metabolism.
- TIP30 promoter methylation is linked to tumor prognosis.
Purpose of the Study:
- To conduct a systematic meta-analysis.
- To explore the clinicopathological and prognostic significance of TIP30 in tumor patients.
Main Methods:
- Searched PubMed and EMBASE databases.
- Manually searched journals and textbooks.
- Performed subgroup analyses based on region, quality, pathology, and patient numbers.
Main Results:
- Included 14 studies with 1705 patients.
- High TIP30 expression associated with good overall survival (HR=0.53) and recurrence-free survival (HR=0.49).
- Lack of TIP30 expression linked to lymph node metastasis (OR=3.90) and advanced clinical stage (OR=2.10). TIP30 promoter methylation did not significantly impact survival.
Conclusions:
- TIP30 expression indicates a favorable prognosis in cancer patients.
- Further large-scale, standardized studies are needed to confirm the TIP30-prognosis relationship.
More Related Videos
07:41Performing Data Mining And Integrative Analysis Of Biomarker in Breast Cancer Using Multiple Publicly Accessible Databases
Published on: May 17, 2019
09:40Author Spotlight: Unveiling the Role of TMOD3 in Platinum Resistance and Immune Infiltration in Ovarian Cancer
Published on: August 2, 2024